Psoriasis occurring after myeloablative therapy and autologous stem cell transplantation.
Wahie
S
S
Alexandroff
A
A
Reynolds
N J
NJ
Meggit
S J
SJ
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000628:therapy*; D016399:Lymphoma, T-Cell / Q000276:immunology / Q000628:therapy*; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D011565:Psoriasis / Q000209:etiology* / Q000276:immunology; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone